Gonadorelin (Factrel, Lutrepulse)
Gonadorelin (Gonadotropin-Releasing Hormone, GnRH, LHRH)
Previously FDA-approved (Factrel and Lutrepulse Kit, both discontinued). No currently marketed FDA-approved product exists. Available through 503A/503B compounding pharmacies by prescription.
A synthetic version of a natural brain hormone that controls reproductive hormone release, previously FDA-approved for diagnostic use and for treating certain menstrual disorders. It is now commonly used alongside testosterone therapy to help preserve fertility and testicular function.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Gonadorelin is generally very well tolerated, consistent with it being structurally identical to an endogenous hormone. In the systematic review of gonadotropin therapy for HH (PMID 38128110), the pooled proportion of patients experiencing gynecomastia with GnRH therapy was 4% (95% CI 0%-10%), acne was 5% (95% CI 0%-37%), and injection site reactions were 42% (95% CI 9%-78%). The injection site reaction rate was elevated by pulsatile pump delivery. The main safety concern is that repeated daily dosing at 200-400mcg can cause GnRH receptor desensitization and paradoxical suppression of LH/FSH within 10-14 days. Single or intermittent dosing does not carry this risk.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-10]